Zhaoke Ophthalmology (HKG:6622) has enrolled the first patient in the phase III clinical trial of Cyclosporine (CsA) Ophthalmic Gel, an April 17 Hong Kong bourse filing said.
The ophthalmic pharmaceutical company is testing the drug for the treatment of moderate to severe dry eye disease.
The trial will involve 25 centers and enroll a total of 360 patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.